Top

Published in:

01-07-2009 | Brief Report

Association of antiphosphatidylserine/prothrombin antibodies with neuropsychiatric systemic lupus erythematosus

Authors: Tomoko Syuto, Akira Shimizu, Yuko Takeuchi, Setsuko Tanaka, Michiko Hasegawa, Yayoi Nagai, Atsushi Tamura, Osamu Ishikawa

Published in: Clinical Rheumatology | Issue 7/2009

Abstract

Neuropsychiatric manifestations in patients with systemic lupus erythematosus (SLE) are well-recognized symptoms although the pathophysiology of neuropsychiatric SLE (NPSLE) is unclear. Since an association with antiphospholipid antibodies has been reported, we examined the prevalence of antiphosphatidylserine–prothrombin antibodies (anti-PS/PT Abs), lupus anticoagulant (LA), anticardiolipin/β2-glycoprotein I antibodies (anti-β2-GPI Abs), and antiribosomal P protein antibodies (antiribosomal P Abs) in 68 SLE patients and analyzed their associations with neuropsychiatric manifestations. The prevalence of LA was significantly higher in the patients with neuropsychiatric (NP) features than those without NP features (P < 0.02). The levels of anti-PS/PT antibody were also significantly higher in the patients with NP features than those without NP features (P < 0.01). The results indicate that LA positivity and higher levels of anti-PS/PT antibody can be predictive markers for NPSLE.

Zandman-Goddard G, Chapman J, Shoenfeld Y (2007) Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 36:297–315PubMedCrossRef

Sanna G, Bertolaccini M, Cuadrado M, Laing H, Khamashta M, Mathieu A et al (2003) Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30:985–992PubMed

Avcin T, Benseler S, Tyrrell P, Cucnik S, Silverman E (2008) A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum 59:206–213PubMedCrossRef

Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef

Karassa F, Afeltra A, Ambrozic A, Chang DM, Keyser FD, Doria A et al (2006) Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 54:312–324PubMedCrossRef

Rheumatol (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42:599–608CrossRef

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306PubMedCrossRef

Nojima J, Kuratsune H, Suehisa E, Kitani T, Iwatani Y, Kanakura Y (2004) Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies—co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 91:967–976PubMed

Nojima J, Iwatani Y, Suehisa E, Kuratsune H, Kanakura Y (2006) The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus. Haematologica 91:699–702PubMed

10.

Nojima J, Masuda Y, Iwatani Y, Kuratsune H, Watanabe Y, Suehisa E et al (2008) Arteriosclerosis obliterans associated with anti-cardiolipin antibody/beta2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus. Rheumatology (Oxford) 47:684–689CrossRef

11.

Hasegawa M, Sato S, Yanaba K, Komura K, Yamazaki M, Takehara K (2004) Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis. Ann Rheum Dis 63:1514–1517PubMedCrossRef

12.

Hanly J, McCurdy G, Fougere L, Douglas J, Thompson K (2004) Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 31:2156–2162PubMed

13.

Sibbitt WJ, Brandt J, Johnson C, Maldonado M, Patel S, Ford C et al (2002) The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 29:1536–1542PubMed

14.

Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ et al (2007) Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 56:265–273PubMedCrossRef

15.

Khamashta M, Gil A, Anciones B, Lavilla P, Valencia M, Pintado V et al (1988) Chorea in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 47:681–683PubMedCrossRef

16.

Ghosh J, Gupta D (2005) Chorea and microphonia as presenting feature of SLE. Indian J Pediatr 72:85CrossRef

17.

Watanabe T, Onda H (2004) Hemichorea with antiphospholipid antibodies in a patient with lupus nephritis. Pediatr Nephrol 19:451–453PubMedCrossRef

Title: Association of antiphosphatidylserine/prothrombin antibodies with neuropsychiatric systemic lupus erythematosus
Authors: Tomoko Syuto
Akira Shimizu
Yuko Takeuchi
Setsuko Tanaka
Michiko Hasegawa
Yayoi Nagai
Atsushi Tamura
Osamu Ishikawa
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: Clinical Rheumatology / Issue 7/2009
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-009-1123-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2009

Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients

Skin and muscle involvement as presenting symptoms in four children with familial Mediterranean fever

HIV polyarteritis nodosa-like vasculitis presenting as chronic abdominal pain

Rickettsioses presenting as major joint arthritis and erythema nodosum: description of four patients

The effectiveness and safety of mycophenolate mofetil in lupus nephritis

Effects of a hand-joint protection programme with an addition of splinting and exercise

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials